Ferroptosis in Cancer Cell Biology.
Bebber CM, Müller F, Prieto Clemente L, Weber J, von Karstedt S. · 2020
Read Ferroptosis in Cancer Cell Biology. by Bebber CM, Müller F, Prieto Clemente L, Weber J, von Karstedt S. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7016816.txt.
Introduction
Bebber and co-authors review ferroptosis in the journal Cancers. Ferroptosis is a form of regulated cell death driven by iron and by damage to cell membrane lipids. It differs from apoptosis and other death routes. Cancer cells that escape those routes may stay open to this one.
The review lays out how ferroptosis is switched on and held back. Two defence proteins, GPX4 and FSP1, block the lipid damage that drives it. The authors then trace links to cancer cell metabolism and oxidative stress. They also cover a possible role in tumour suppression and tumour immunology. Their aim is to point to new ways to use ferroptosis in cancer treatment.
Catalog record
| CREATOR | Bebber CM, Müller F, Prieto Clemente L, Weber J, von Karstedt S. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 95 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Ferroptosis in Cancer Cell Biology By Christina M Bebber, Fabienne Müller, Laura Prieto Clemente, Josephine Weber, Silvia von Karstedt Published in: Cancers DOI: 10.3390/cancers12010164 ABSTRACT Abstract A major hallmark of cancer is successful evasion of regulated forms of cell death. Ferroptosis is a recently discovered type of regulated necrosis which, unlike apoptosis or necroptosis, is independent of caspase activity and receptor-interacting protein 1 (RIPK1) kinase activity. Instead, ferroptotic cells die following iron-dependent lipid peroxidation, a process which is antagonised by glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1). Importantly, tumour cells escaping other forms of cell death have been suggested to maintain or acquire sensitivity to ferroptosis. Therefore, therapeutic exploitation of ferroptosis in cancer has received increasing attention. Here, we systematically review current literature on ferroptosis signalling, cross-signalling to cellular metabolism in cancer and a potential role for ferroptosis in tumour suppression and tumour immunology. By summarising current findings on cell biology relevant to ferroptosis in cancer, we aim to point out new conceptual avenues for utilising ferroptosis in systemic treatment approaches for cancer. Keywords: ferroptosis, cancer, cell death, GPX4, inflammation 1. INTRODUCTION The emergence of electron transport chains as a means to generate a chemical gradient for the generation of adenosine triphosphate (ATP) is as ancient as the first single-celled organism undergoing photosynthesis to produce oxygen. Billions of years of evolution later, multicellular aerobic organisms generate ATP mainly by oxidative phosphorylation (OXPHOS) at the expense of atmospheric oxygen [1]. Herein, protein complexes belonging to the electron transport chain are located in the inner mitochondrial membrane where they transport electrons derived from nicotinamide adenine dinucleotide hydrogen (NADH) via redox reduction to the terminal electron acceptor oxygen (O2), which is thereby reduced to water (H2O). NADH is one of the major products of the tricarboxylic acid (TCA) cycle within the mitochondrial lumen driven by metabolites such as Acetyl-CoA derived from glycolysis and catabolic fatty acid oxidation (β-oxidation) [1]. During electron transport, a small proportion of electrons leak out and react with oxygen molecules to generate highly reactive superoxide (O∙−2) [2]. Superoxides can be transported into the cytosol using the mitochondrial permeability transition pore (mPTP) in the outer mitochondrial membrane. Thereby, OXPHOS is a major source of reactive oxygen species (ROS) in aerobic cells which can cause aberrant oxidation of proteins, lipids and DNA. Therefore, cells have evolved to develop a complex cellular antioxidant defence system to ensure cellular survival. As such, superoxide dismutases (SOD1), localised either in the cytoplasm or in the mitochondrial matrix (SOD2), catalyse the dismutation of superoxides (O∙−2) generated during OXPHOS into slightly less reactive hydrogen peroxide (H2O2) and water (H2O) [2]. H2O2 is then further reduced by catalases, glutathione peroxidases (GPXs) or peroxiredoxins (PRDXs) [3]. Many antioxidant defence proteins including SOD1, catalase and glutathione peroxidase 4 (GPX4) [4] are transcriptionally induced by the antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) which is activated upon oxidative stress-induced degradation of its negative regulator kelch-associated protein 1 (KEAP1) [5]. Yet, in the presence of redox-active metals such as divalent iron (Fe2+) catalysing the Fenton reaction, hydroxyl radicals (HO∙) are generated from hydrogen peroxide (H2O2) [6]. Hence, limiting the availability of free divalent redox-active metals via sequestration within metal-binding proteins is an additional integral part of the cellular antioxidant defence machinery [7]. Paradoxically, despite OXPHOS being the most efficient way to generate ATP, many cancer cells have undergone metabolic reprogramming, wherein they mainly generate ATP from cytosolic aerobic glycolysis coupled to lactate fermentation. This metabolic re-programming in cancer was famously discovered by Warburg and Cori in the 1920s [8,9] and has been suggested as a cancer cell means to evade toxic levels of ROS production. However, maintenance of this Warburg effect requires higher glucose uptake and elevated metabolic activity making tumour cells nevertheless heavily reliant on the antioxidant machinery and maybe even more susceptible to oxidative stress [10,11]. Therefore, highly proliferative cancer cells are known to require handling of elevated cellular ROS levels in order to successfully establish tumours [12,13,14]. One of the most important hallmarks of cancer is the efficient evasion of regulated cell death. Recently, ferroptosis, a new, yet potentially evolutionary ancient type of regulated necrosis which is triggered upon collapse of a lipid radical-specific antioxidant defence system was described [15] (recently also reviewed [16,17,18,19,20]). Whereas apoptosis, necroptosis and pyroptosis are all either directly dependent on caspases or inhibited by their activity (reviewed in-depth elsewhere [21]), ferroptosis seems to have evolved separately with, as of yet, very little known direct molecular cross-talk to other pathways of regulated cell death [21]. As the study of ferroptosis is a relatively young, yet rapidly growing field, here, we will provide an updated systemic overview on processes regulating ferroptosis and potential outcomes in cancer. 2. FERROPTOSIS PATHWAY REGULATION One hallmark of ferroptosis is the requirement for iron, as demonstrated by the fact that chelation of iron by deferoxamine (DFO) rescues experimental induction of ferroptosis [15]. Consequently, transferrin, which binds free ferric iron (Fe3+) and shuttles it into cells, was shown to regulate ferroptosis [22]. Once Fe3+ is imported, endosomal six-transmembrane epithelial antigen of prostate 3 (STEAP3) catalyses the reduction to divalent iron (Fe2+) and releases it to the cellular labile iron pool through the divalent metal transporter 1 (DMT1) [23]. Interestingly, DMT1 has been shown to be up-regulated upon ferroptosis-induction [24]. Another hallmark is the characteristic accumulation of membrane lipid peroxides preceding cell death [15]. Lipid peroxides were recently modelled to destabilise the lipid bilayer resulting in disintegration of cellular membranes in silico [25]. Through the use of lipidomics, arachidonic acid (AA)- and adrenic acid (AdA)-containing phosphatidylethanolamine (PE) species were identified as in vivo lipid products of ferroptosis [26]. These lipids can undergo spontaneous peroxidation in the presence of hydroxyl radicals (HO∙) generated from Fenton reactions of redox active divalent iron (Fe2+) and hydroperoxide (H2O2). Hydroxyl radicals (HO∙) can react directly with polyunsaturated fatty acids (PUFAs) in membrane phospholipids which can trigger a chain reaction of lipid ROS attacking proximal PUFAs. Alternatively, divalent iron can serve as a cofactor for lipoxygenase (LOX) to catalyse PUFA peroxidation enzymatically [27]. PUFAs are especially sensitive to lipid peroxidation due to the presence of highly reactive hydrogen atoms within methylene bridges [28]. Interestingly, 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) are fairly specific lipid peroxidation by-products, which have frequently been used as general markers of oxidative stress in tissue sections. Acyl-CoA synthetase long-chain family member 4 (ACSL4) mediates esterification of AA and AdA with coenzyme A (CoA) forming Acyl-CoA which can then undergo either ß-oxidation or anabolic PUFA biosynthesis [29,30,31]. Importantly, ACSL4 was identified to be required for cells to undergo ferroptosis by generating the lipid target pool for peroxidation [20,29]. In a similar manner, lysophosphatidylcholine acyltransferase 3 (LPCAT3) contributes to ferroptosis by incorporation of AA into phospholipids of cellular membranes thereby contributing to substrate generation for lipid peroxidation [29,32,33]. Together, these findings demonstrate that PUFA synthesis and peroxidation is an essential prerequisite for cells to die via ferroptosis. Vice versa, GPX4 was shown to constitutively hydrolyse lipid hydroperoxides and thereby serve cellular protection from ferroptosis [34]. Antagonising GPX4 with the small molecule inhibitor rat sarcoma viral oncogene homolog (RAS)-selective lethal 3 (RSL3) led to efficient induction of ferroptosis [15]. GPX4 requires glutathione (GSH)